Skip to main content

The Real-World Evidence Platform is supported by the CMRG national myeloma database which houses real world data for over 8000 patients from time of diagnosis to most current treatment. Our database is one of the largest and most comprehensive databases of myeloma patients in the world.

The national CMRG database provides insight into the regional differences in myeloma treatment approaches. As of 2021, patients from 17 sites across Canada have been logged into our database, with data dating back to 2007.

  • Allows evaluation of myeloma treatment outcomes in real-world setting
  • Allows identification of treatment landscape, regional differences, strengths, and areas for improvements
  • Identifies research priorities for CMRG clinical trial design
  • Identify gaps targeted for rapid trial accrual
  • Provides benchmarks with which to compare future treatments
  • Supports/Informs treatment approval and/or reimbursement decisions

We have completed over 10 database studies with additional analyses in progress

  • CMRG-DB-001 – Cyclophosphamide, Bortezomib and Dexamethasone compared to Lenalidomide and Dexamethasone for non transplant eligible MM patients
  • CMRG-DB-002 – The Survival Impact of Lenalidomide Maintenance Chemotherapy in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplant and Bortezomib-Based Induction
  • CMRG-DB-003 – Real-world treatment patterns and outcomes in patients with relapsed or refractory multiple myeloma (RRMM) who have progressed on prior treatment containing lenalidomide during Jan 2007 to Apr 2019 in Canada
  • CMRG-DB-005 – Single versus tandem transplant for multiple myeloma with high risk cytogenetics
  • CMRG-DB-006 – Sequential use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database 
  • CMRG-DB-007 – Outcomes of Daratumumab Containing Regimens in Patients with Multiple Myeloma Progressing on Lenalidomide Maintenance: Real-World Experience from Canadian and Germany Centers
  • CMRG-DB-008 – Real world data on Carfilzomib usage and outcomes in patients with multiple myeloma: A Multi-Institutional Report from the National Canadian Myeloma Research Group (CMRG) Database
  • CMRG-DB-009 – Real world data on lenalidomide maintenance dosing and outcomes in transplant eligible patients with newly-diagnosed multiple myeloma
  • CMRG-DB-010 – Impact of Daratumumab in the treatment of multiple myeloma in the real-world setting: outcomes on therapy and beyond
  • CMRG-DB-012 – Benchmarking Study In Canadian Patients with Multiple Myeloma Using The Canadian Myeloma Research Group Database